Skip to main content
SpringerLink
Log in

New Drugs for Thromboprophylaxis: Apixaban, Dabigatran, Rivaroxaban

  • Chapter
  • First Online:
Thromboembolism in Orthopedic Surgery

Abstract

Recently, new direct oral anticoagulant agents have been developed, and some of them have received approval for thromboprophylaxis after hip or knee arthroplasty, with other medical and surgical indications being accepted or investigated in several ongoing studies. The most developed ones are apixaban, rivaroxaban, and dabigatran. This chapter provides a review of their pharmacology and a temporary update of their indications, giving the basis for their management in orthopedic surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Geerts WH, Bergqvist D, Pineo GF, Heilt JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guideline (8th edition). Chest. 2008;133:381S–435.

    Article  PubMed  CAS  Google Scholar 

  2. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs. Chest. 2008;133:234S–56.

    Article  PubMed  CAS  Google Scholar 

  3. Hirsh J, O’Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105:453–63.

    Article  PubMed  CAS  Google Scholar 

  4. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly. 2009; 139:60–4.

    PubMed  CAS  Google Scholar 

  5. Llau JV, Ferrandis R. New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol. 2009;22(5):661–6.

    Article  PubMed  Google Scholar 

  6. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15–20.

    Article  PubMed  CAS  Google Scholar 

  7. Galanis T, Thomson L, Palladino M, Merli GJ. New oral anticoagulants. J Thromb Thrombolysis. 2011;31:310–20.

    Article  PubMed  CAS  Google Scholar 

  8. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humpreys WG. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1): 74–81.

    Article  PubMed  CAS  Google Scholar 

  9. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors development. Clin Pharmacokinet. 2009;48: 1–22.

    Article  PubMed  CAS  Google Scholar 

  10. Eliquis (apixaban). Summary of product characteristics, Bristol Myers Squibb/Pfizer EEIG. http://ec.europa.eu/health/documments/community-register/2011/20110518102349/anx_102349-en.pdf. (Accessed March 30th 2012)

  11. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594–604.

    Article  PubMed  CAS  Google Scholar 

  12. Lassen MR, Raskob GE, Galus A, Pineo G, Chen D, Hornick P, the ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet. 2010;375:807–15.

    Article  PubMed  CAS  Google Scholar 

  13. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, the ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487–98.

    Article  PubMed  CAS  Google Scholar 

  14. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, for the AVERROES Steering Committee and Investigators, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.

    Article  PubMed  CAS  Google Scholar 

  15. APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877–85.

    Article  Google Scholar 

  16. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–9.

    Article  PubMed  CAS  Google Scholar 

  17. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for thromboprophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008;28:1354–73.

    Article  PubMed  CAS  Google Scholar 

  18. Stangier J, Rathgen K, Staehle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.

    Article  PubMed  CAS  Google Scholar 

  19. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–40.

    Article  PubMed  Google Scholar 

  20. Stangier J, Rathgen K, Stahle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs. 2009;9:59–68.

    PubMed  CAS  Google Scholar 

  21. Stangier J, Stahle H, Rathgen K. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin (abstract). J Thromb Haemost. 2007;5(52):P-W 672.

    Google Scholar 

  22. Pradaxa (dabigatran etexilate). Summary of product characteristics. Boehringer Ingelheim International GmbH. http://www.pradaxa.com/Include/media/pdf/Pradaxa_SPC_EMEA.pdf. (Accessed march 30th 2012)

  23. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, RE-NOVATE Study Group, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, noninferioritytrial. Lancet. 2007;370:949–56.

    Article  PubMed  CAS  Google Scholar 

  24. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178–85.

    Article  PubMed  CAS  Google Scholar 

  25. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, et al. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;2:1–9.

    Google Scholar 

  26. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.

    Article  PubMed  CAS  Google Scholar 

  27. Connolly SJ, Esekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  PubMed  CAS  Google Scholar 

  28. Wann LS, Curtis AB, Ellenbogen KA, Estes 3rd NA, Ezekowitz MD, Jackman WM, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57(11):1330–7.

    Article  PubMed  Google Scholar 

  29. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, for the RE-DEEM investigators, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781. Epub ahead of print.

    Article  PubMed  CAS  Google Scholar 

  30. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939 an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412–21.

    Article  PubMed  CAS  Google Scholar 

  31. Eriksson BI, Borris LC, Friedman RJ, Haas S, Himan MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358: 2765–75.

    Article  PubMed  CAS  Google Scholar 

  32. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind randomized controlled trial. Lancet. 2008;372:31–9.

    Article  PubMed  CAS  Google Scholar 

  33. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, RECORD 3 Investigators, et al. Rivaroxaban for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–85.

    Article  PubMed  CAS  Google Scholar 

  34. Turpie A, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, RECORD 4 Investigators, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet. 2009;373:1673–80.

    Article  PubMed  CAS  Google Scholar 

  35. Xarelto (rivaroxaban). Summary of product characteristics. Bayer Schering Pharma. http://www.xarelto.com. (Accessed march 30th 2012).

  36. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46(5):549–58.

    Article  PubMed  CAS  Google Scholar 

  37. The Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Eng J Med. 2010;363:2499–510.

    Article  Google Scholar 

  38. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, the ROCKET AF Steering Committee, for the ROCKET AF Investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  PubMed  CAS  Google Scholar 

  39. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal–epidural anesthesia. Anesth Analg. 1994;79:1165–77.

    Article  PubMed  CAS  Google Scholar 

  40. Rosencher N, Bonnet MP, Sessler DI. Selected new antithrombotic agents and neuraxial anaesthesia for major orthopedic surgery: management strategies. Anaesthesia. 2007;62:1154–60.

    Article  PubMed  CAS  Google Scholar 

  41. Wulf H. Epidural anaesthesia and spinal haematoma. Can J Anaesth. 1996;43:1260–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anaesthesiology and Critical Care, Hospital Clinic Universitari de València, Avda Blasco Ibáñez 17, 46006, Valencia, Spain

    Raquel Ferrandis M.D., Ph.D.

  2. Human Physiology Department, School of Medicine, Valencia University, Valencia, Spain

    Raquel Ferrandis M.D., Ph.D.

Authors
  1. Raquel Ferrandis M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raquel Ferrandis M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. , Department of Anaesthesiology and Critic, University Hospital of Valencia, Valencia, 46010, Spain

    Juan V. Llau

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Ferrandis, R. (2013). New Drugs for Thromboprophylaxis: Apixaban, Dabigatran, Rivaroxaban. In: Llau, J. (eds) Thromboembolism in Orthopedic Surgery. Springer, London. https://doi.org/10.1007/978-1-4471-4336-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4336-9_6

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4335-2

  • Online ISBN: 978-1-4471-4336-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation